These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
507 related articles for article (PubMed ID: 37242657)
1. Challenges and Opportunities in the Oral Delivery of Recombinant Biologics. Masloh S; Culot M; Gosselet F; Chevrel A; Scapozza L; Zeisser Labouebe M Pharmaceutics; 2023 May; 15(5):. PubMed ID: 37242657 [TBL] [Abstract][Full Text] [Related]
2. Nanocarriers for oral delivery of biologics: small carriers for big payloads. Cao Y; Rewatkar P; Wang R; Hasnain SZ; Popat A; Kumeria T Trends Pharmacol Sci; 2021 Nov; 42(11):957-972. PubMed ID: 34593258 [TBL] [Abstract][Full Text] [Related]
3. Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model. Masloh S; Chevrel A; Culot M; Perrocheau A; Kalia YN; Frehel S; Gaussin R; Gosselet F; Huet S; Zeisser Labouebe M; Scapozza L Pharmaceutics; 2024 Jan; 16(1):. PubMed ID: 38258126 [TBL] [Abstract][Full Text] [Related]
4. Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability. Verma S; Goand UK; Husain A; Katekar RA; Garg R; Gayen JR Drug Dev Res; 2021 Nov; 82(7):927-944. PubMed ID: 33988872 [TBL] [Abstract][Full Text] [Related]
5. An overview of in vitro, ex vivo and in vivo models for studying the transport of drugs across intestinal barriers. Xu Y; Shrestha N; Préat V; Beloqui A Adv Drug Deliv Rev; 2021 Aug; 175():113795. PubMed ID: 33989702 [TBL] [Abstract][Full Text] [Related]
6. Exploiting disease-induced changes for targeted oral delivery of biologics and nanomedicines in inflammatory bowel disease. Zhang Y; Thanou M; Vllasaliu D Eur J Pharm Biopharm; 2020 Oct; 155():128-138. PubMed ID: 32853696 [TBL] [Abstract][Full Text] [Related]
8. Intestinal Permeability and Drug Absorption: Predictive Experimental, Computational and In Vivo Approaches. Dahlgren D; Lennernäs H Pharmaceutics; 2019 Aug; 11(8):. PubMed ID: 31412551 [TBL] [Abstract][Full Text] [Related]
9. Oral Delivery of Biologics for Precision Medicine. Durán-Lobato M; Niu Z; Alonso MJ Adv Mater; 2020 Apr; 32(13):e1901935. PubMed ID: 31222910 [TBL] [Abstract][Full Text] [Related]
10. Recent advances in oral delivery of biologics: nanomedicine and physical modes of delivery. Vllasaliu D; Thanou M; Stolnik S; Fowler R Expert Opin Drug Deliv; 2018 Aug; 15(8):759-770. PubMed ID: 30033780 [TBL] [Abstract][Full Text] [Related]
11. A robotic pill for oral delivery of biotherapeutics: safety, tolerability, and performance in healthy subjects. Dhalla AK; Al-Shamsie Z; Beraki S; Dasari A; Fung LC; Fusaro L; Garapaty A; Gutierrez B; Gratta D; Hashim M; Horlen K; Karamchedu P; Korupolu R; Liang E; Ong C; Owyang Z; Salgotra V; Sharma S; Syed B; Syed M; Vo AT; Abdul-Wahab R; Wasi A; Yamaguchi A; Yen S; Imran M Drug Deliv Transl Res; 2022 Jan; 12(1):294-305. PubMed ID: 33604838 [TBL] [Abstract][Full Text] [Related]
12. Oral inhalation for delivery of proteins and peptides to the lungs. Fröhlich E; Salar-Behzadi S Eur J Pharm Biopharm; 2021 Jun; 163():198-211. PubMed ID: 33852968 [TBL] [Abstract][Full Text] [Related]
13. Intestinal iontophoresis from mucoadhesive patches: a strategy for oral delivery. Banerjee A; Chen R; Arafin S; Mitragotri S J Control Release; 2019 Mar; 297():71-78. PubMed ID: 30707901 [TBL] [Abstract][Full Text] [Related]
14. Strategies for non-invasive delivery of biologics. Chung SW; Hil-lal TA; Byun Y J Drug Target; 2012 Jul; 20(6):481-501. PubMed ID: 22632037 [TBL] [Abstract][Full Text] [Related]
15. Potential of Lipid Nanoparticles (SLNs and NLCs) in Enhancing Oral Bioavailability of Drugs with Poor Intestinal Permeability. Talegaonkar S; Bhattacharyya A AAPS PharmSciTech; 2019 Feb; 20(3):121. PubMed ID: 30805893 [TBL] [Abstract][Full Text] [Related]
16. Improving oral absorption via drug-loaded nanocarriers: absorption mechanisms, intestinal models and rational fabrication. Shahbazi MA; Santos HA Curr Drug Metab; 2013 Jan; 14(1):28-56. PubMed ID: 22497568 [TBL] [Abstract][Full Text] [Related]
17. The biological challenges and pharmacological opportunities of orally administered nanomedicine delivery. Moss DM; Curley P; Kinvig H; Hoskins C; Owen A Expert Rev Gastroenterol Hepatol; 2018 Mar; 12(3):223-236. PubMed ID: 29088978 [TBL] [Abstract][Full Text] [Related]
18. The enhanced intestinal permeability of infant mice enables oral protein and macromolecular absorption without delivery technology. Gleeson JP; Fein KC; Chaudhary N; Doerfler R; Newby AN; Whitehead KA Int J Pharm; 2021 Jan; 593():120120. PubMed ID: 33249250 [TBL] [Abstract][Full Text] [Related]
19. Modeling gastrointestinal drug absorption requires more in vivo biopharmaceutical data: experience from in vivo dissolution and permeability studies in humans. Lennernäs H Curr Drug Metab; 2007 Oct; 8(7):645-57. PubMed ID: 17979653 [TBL] [Abstract][Full Text] [Related]
20. Advances and applications of chitosan-based nanomaterials as oral delivery carriers: A review. Lang X; Wang T; Sun M; Chen X; Liu Y Int J Biol Macromol; 2020 Jul; 154():433-445. PubMed ID: 32194103 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]